Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis
- PMID: 15557209
- DOI: 10.1369/jhc.4A6438.2004
Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis
Abstract
Pulmonary lymphangioleiomyomatosis (LAM) is characterized by abnormal proliferation of immature-looking smooth muscle (SM)-like cells (LAM cells), leading to lung destruction and cyst formation. In addition to expressing some SM markers, scattered LAM cells express the melanocytic maker gp100, which is recognized by antibody HMB45, suggesting that at least a few LAM cells may have melanocytic differentiation. Here we immunostained 26 LAM samples for several melanocyte-related proteins. These studies showed that all LAM cells express tetraspanin CD63, a melanoma-associated protein that belongs to the transmembrane 4 superfamily. The majority of LAM cells also immunoreacted with PNL2, an antibody against a yet uncharacterized melanocytic antigen. Furthermore, we examined the co-expression of PNL2 and Ki-67, an indicator of cell proliferation, and found that PNL2-positive LAM cells showed a significantly lower proliferation rate compared with their negative counterparts. Our findings shed new light on the nature of the LAM cells by demonstrating their combined SM and melanocytic differentiation and the existence of subpopulations with different proliferative potential. Furthermore, these studies provided two new antibodies useful in the diagnosis of LAM.
Similar articles
-
Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.Am J Respir Cell Mol Biol. 1999 Sep;21(3):327-36. doi: 10.1165/ajrcmb.21.3.3693. Am J Respir Cell Mol Biol. 1999. PMID: 10460750
-
[Pulmonary lymphangioleiomyomatosis. Morphologic and immunohistochemical findings].Pathologe. 2001 May;22(3):197-204. doi: 10.1007/s002920100462. Pathologe. 2001. PMID: 11402850 German.
-
Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis.J Pathol. 2004 Jun;203(2):653-60. doi: 10.1002/path.1577. J Pathol. 2004. PMID: 15141380
-
A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Am J Respir Cell Mol Biol. 2012 Jan;46(1):1-5. doi: 10.1165/rcmb.2011-0215TR. Am J Respir Cell Mol Biol. 2012. PMID: 21940815 Review.
-
Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26. doi: 10.1513/pats.200705-061VS. Proc Am Thorac Soc. 2008. PMID: 18094094 Free PMC article. Review.
Cited by
-
Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Endocrinology. 2016 Sep;157(9):3374-83. doi: 10.1210/en.2016-1395. Epub 2016 Jul 13. Endocrinology. 2016. PMID: 27409646 Free PMC article. Review.
-
Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.J Pathol Clin Res. 2020 Jul;6(3):215-226. doi: 10.1002/cjp2.162. Epub 2020 Apr 30. J Pathol Clin Res. 2020. PMID: 32352655 Free PMC article.
-
Lymphangioleiomyomatosis: what do we know and what are we looking for?Eur Respir Rev. 2011 Mar;20(119):34-44. doi: 10.1183/09059180.00011010. Eur Respir Rev. 2011. PMID: 21357890 Free PMC article. Review.
-
The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.Front Cell Dev Biol. 2014 Nov 25;2:69. doi: 10.3389/fcell.2014.00069. eCollection 2014. Front Cell Dev Biol. 2014. PMID: 25505789 Free PMC article. Review.
-
Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.PLoS One. 2012;7(6):e38589. doi: 10.1371/journal.pone.0038589. Epub 2012 Jun 15. PLoS One. 2012. PMID: 22719903 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous